Other meanings of Drug development
PHARMACEUTICAL SCIENCE
Drug development is the process of discovering, testing, and bringing pharmaceutical drugs to market. It links laboratory research, formulation, toxicology, clinical trials, regulatory review, manufacturing, and post-market surveillance. A candidate must show an acceptable balance of benefits and risks for a defined population before a regulator can authorize its sale, and evidence continues to accumulate after approval.
Drug development begins by identifying a biological problem and a molecule or other intervention that might address it. Researchers may start with disease mechanisms, human genetic evidence, natural products, antibodies, nucleic acids, or computationally designed compounds. Screening and medicinal chemistry then examine potency, selectivity, stability, absorption, and possible toxicity. The selected candidate is developed into a usable dosage form, such as a tablet, injection, or biologic formulation.
Before first-in-human testing, sponsors conduct preclinical studies using laboratory systems and, where required, animals to characterize pharmacology, toxicology, exposure, and manufacturing quality. The resulting evidence supports an Investigational New Drug application in the United States or a comparable national submission elsewhere. Regulatory authorities review whether the proposed studies adequately protect participants and whether the product has a reasonable basis for clinical testing.
Clinical trials determine how a candidate behaves in people and whether its benefits outweigh its risks. Phase I studies usually emphasize safety, tolerability, and dose while collecting pharmacokinetic data; phase II explores biological activity and dose selection; and phase III generally tests efficacy and safety in larger, more representative populations, often against placebo or standard treatment.
Trial design includes eligibility criteria, endpoints, controls, randomization, blinding, statistical plans, and procedures for reporting adverse events. Registration and public reporting requirements improve transparency, although results can still be difficult to compare when endpoints or populations differ. Some products receive special designs, such as adaptive trials, platform trials, or studies using surrogate endpoints, when conventional development would be unusually slow or impractical.
Regulatory review examines a product’s quality, safety, efficacy, labeling, and manufacturing controls. In the United States, a small-molecule drug is commonly submitted through a New Drug Application, while many biological products use a Biologics License Application; other jurisdictions apply their own legal pathways. Reviewers assess the complete evidence package, including clinical data, nonclinical findings, chemistry and manufacturing information, and proposed instructions for use.
Approval does not end development. Manufacturing sites must maintain validated processes and quality systems, while sponsors monitor adverse events and may conduct post-marketing studies. Accelerated or conditional pathways can permit earlier access for serious conditions when preliminary evidence is compelling, but they may require confirmatory trials and can lead to restrictions or withdrawal if expected benefits are not verified.
Drug development is shaped as much by failure, reformulation, and evidence design as by successful discovery. A candidate may be abandoned because it cannot reach the right tissue, has an unfavorable interaction profile, proves difficult to manufacture, or works only in a biomarker-defined subgroup. Conversely, an existing medicine can gain a new indication, formulation, route of administration, or pediatric use without repeating every stage of its original development.
Rare-disease programs illustrate how the standard sequence can be adapted. Small patient populations may require natural-history studies, external controls, or a combination of laboratory biomarkers and clinical outcomes. Pharmacovigilance can also reveal uncommon harms that pre-approval trials are too small to detect. International development adds further complexity because regulators may differ in evidentiary standards, inspection practice, health-technology assessment, and access decisions.12
Development pathways vary by jurisdiction, product type, disease area, and regulatory designation; the sequence described here is a general model rather than a universal timetable.
Help improve the encyclopedia. Reports go straight to the site manager.